![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}
An animal vaccine company that develops and produces vaccines for livestock and companion animals from its own research and sells them in Korea and abroad.
Six animal vaccine lines: SuiShot, PoulShot, BoviShot, CaniShot, FeliShot and AquaShot. The company makes about 85 products for livestock and companion animals and exports to 23 countries.
African swine fever (ASF) vaccine for use in piglets as well as sows and gilts. It received Korea's first export-only product licence for an ASF vaccine, and registration is being pursued in Vietnam and the Philippines.
Manufacturing site in the Dongsan industrial complex, Eunjin-myeon, Nonsan, Chungcheongnam-do.
Head office on Yuseong-daero, Yuseong-gu, Daejeon.
Presented safety, efficacy and stability test data for SuiShot ASF-X at a symposium on ASF epidemiology and vaccine development; the company said it had received Korea's first export-only product licence for an ASF vaccine.
Said ASF vaccine R&D is effectively complete; country registrations are under way in markets including Vietnam and the Philippines, and licensing talks with multinational animal health companies are ongoing.
Won a public-tender contract with the Public Procurement Service to supply 4 million animal doses of foot-and-mouth disease SAT1 vaccine worth KRW 5.8 billion (excluding VAT), for delivery by 7 August 2026.
Reported preliminary Q2 2026 results: revenue of KRW 11.901 billion, operating profit of KRW 1.143 billion and net income of KRW 1.289 billion.
Individual vacancy
Observed 2026-10-26 · Application window Date unconfirmed — 2026-10-29
A brief based on selected official material, not an exhaustive product or vacancy list.